Pain-Related Outcome Domains and Measures in Randomized Controlled Trials of Treatment for Acute Abdominal Pain: A Systematic Review.
European journal of pain (London, England) · 2026
Abstract originale
BACKGROUND AND OBJECTIVES: Acute abdominal pain frequently presents to emergency departments, yet outcome domains in randomized controlled trials (RCTs) remain poorly characterized. This review identified pain-related domains and outcome measures used in RCTs on acute abdominal pain. DATABASES AND DATA TREATMENT: This PRISMA-guided systematic review was registered in PROSPERO (CRD42025630171). PubMed, Embase, Scopus, and Web of Science were searched for RCTs (January 2000-February 2025). Eligible studies included adult and paediatric patients with acute abdominal pain reporting pain assessment. Outcome domains extracted included pain intensity, rescue analgesia, adverse effects, pain interference, quality of life (QoL), and psychological function. Bias was assessed using Cochrane RoB2. RESULTS: Of 826 records, 43 RCTs were included; eight included children. In adult trials, pain intensity was assessed using the visual analogue scale (n = 19) or the numeric rating scale (n = 15). Rescue analgesia (44%) and adverse effects (84%) were frequently reported. No study assessed pain interference or psychological function, and QoL was listed as an outcome in one trial. All were conducted in emergency settings, with short-term follow-up within the first hours. CONCLUSIONS: Pain assessment in acute abdominal pain RCTs is predominantly limited to intensity measures and short-term outcomes. While appropriate for immediate analgesic effects, this approach may be insufficient when broader treatment goals or longer follow-up are relevant. Context-specific outcome selection is needed, aligning domains with clinical purpose and time frame. SIGNIFICANCE: RCTs on acute abdominal pain assess pain incompletely, focusing predominantly on intensity rather than broader domains such as pain interference and psychological function. None adhered to the INTEGRATE framework for pain assessment. This review provides the first systematic mapping of outcome domains in this area, offering a foundation for context-specific outcome selection aligned with what matters to patients.
Parole chiave
Leggi il testo integrale originale
Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.
Pain‐Related Outcome Domains and Measures in Randomized Controlled Trials of Treatment for Acute Abdominal Pain: A Systematic Review
ABSTRACT
Background and Objectives
Acute abdominal pain frequently presents to emergency departments, yet outcome domains in randomized controlled trials (RCTs) remain poorly characterized. This review identified pain‐related domains and outcome measures used in RCTs on acute abdominal pain.
Databases and Data Treatment
This PRISMA‐guided systematic review was registered in PROSPERO (CRD42025630171). PubMed, Embase, Scopus, and Web of Science were searched for RCTs (January 2000–February 2025). Eligible studies included adult and paediatric patients with acute abdominal pain reporting pain assessment. Outcome domains extracted included pain intensity, rescue analgesia, adverse effects, pain interference, quality of life (QoL), and psychological function. Bias was assessed using Cochrane RoB2.
Results
Of 826 records, 43 RCTs were included; eight included children. In adult trials, pain intensity was assessed using the visual analogue scale (n = 19) or the numeric rating scale (n = 15). Rescue analgesia (44%) and adverse effects (84%) were frequently reported. No study assessed pain interference or psychological function, and QoL was listed as an outcome in one trial. All were conducted in emergency settings, with short‐term follow‐up within the first hours.
Conclusions
Pain assessment in acute abdominal pain RCTs is predominantly limited to intensity measures and short‐term outcomes. While appropriate for immediate analgesic effects, this approach may be insufficient when broader treatment goals or longer follow‐up are relevant. Context‐specific outcome selection is needed, aligning domains with clinical purpose and time frame.
Significance
RCTs on acute abdominal pain assess pain incompletely, focusing predominantly on intensity rather than broader domains such as pain interference and psychological function. None adhered to the INTEGRATE framework for pain assessment. This review provides the first systematic mapping of outcome domains in this area, offering a foundation for context‐specific outcome selection aligned with what matters to patients.
1.Introduction
Abdominal pain is the most common reason for contact in emergency departments, accounting for approximately 9% of all visits in the United States (Wu et al. 2025). It ranges from mild diffuse discomfort to severe localized pain, with sensory, affective, and autonomic components (Cervero 2010; Drewes et al. 2020; Xiao and Zhang 2018). Accurate assessment is essential for both diagnosis and pain management, yet abdominal pain can be diagnostically ambiguous: it may originate from multiple visceral or somatic sources, its intensity does not reliably correlate with disease severity (Cervero 1991; Shaballout et al. 2021), and reporting is shaped by psychological factors (Vassend et al. 2013). Clinically, the need for timely analgesia must be balanced against the risk of obscuring diagnostic signs (Villain et al. 2013).
Management of acute abdominal pain remains suboptimal. Adequate analgesia and improved mobilization are often not achieved, and clinical trial evidence does not consistently translate into practice, partly due to mixed findings from randomized controlled trials (RCTs) (Chambers 2018). A key contributing factor is the absence of a comprehensive, standardized approach to pain assessment.
Using a Core Outcome Set (COS) for acute abdominal pain would address this gap. A COS defines the minimum outcomes that should be assessed across all clinical trials and clinical practice for a specific condition, agreed upon by relevant stakeholders including patients (Williamson et al. 2017). Per the Core Outcome Measures in Effectiveness Trials (COMET) initiative, outcome selection should follow a construct‐first principle: domains (e.g., pain intensity, pain interference, physical function) must be defined before selecting measurement instruments, which should be chosen based on construct relevance and measurement properties rather than convenience (Mokkink et al. 2016). A recently developed COS for acute pain in general recommends extending assessment beyond pain intensity to include, at minimum, pain interference, physical function, and quality of life (Bova et al. 2023, 2025). For visceral pain, psychological distress plays a more integral role in both development and amplification than for somatic pain (Sikandar and Dickenson 2012), making psychological domain assessment arguably even more important in this context.
The relevance of specific domains depends on clinical context, stakeholder perspectives, assessment timeframe, and feasibility, all of which vary across settings.
The first step in developing a COS is to map what has already been measured in existing trials (Williamson et al. 2017). This systematic review therefore aims to map and critically evaluate the domains, outcome measures, and contextual factors used to assess pain in RCTs of acute abdominal pain, serving as a foundation for the possible future development of a COS for acute abdominal pain.
2.Methods
This systematic review was conducted in accordance with PRISMA 2020 guidelines (Page et al. 2021) and was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO; ID: CRD42025630171). No protocol beyond registration was prepared.
2.1.Eligibility Criteria
We included RCTs that investigated patients experiencing acute abdominal (visceral) pain of any cause, excluding studies focused solely on postoperative pain or acute pancreatitis, which are covered by separate reviews within our research group (Prospero; ID: CRD420251121922 (Joseph et al. 2025)). Eligible studies had to report pain assessment methods as part of the trial methodology. Data extraction focused on domains (based on recommendations from the COMET initiative (Williamson et al. 2017)) and measures, both unidimensional (e.g., Visual Analogue Scale [VAS], Numeric Rating Scale [NRS]) and multidimensional (e.g., McGill Pain Questionnaire), regardless of whether they are validated or exploratory, related to acute abdominal pain. Only studies published in English from 1 January 2000, up to 3 February 2025, were considered. Studies were excluded if they were non‐RCTs, non‐human studies, studies focused exclusively on chronic pain (three months or longer), or if data on acute pain or mixed populations could not be extracted separately.
2.2.Information Sources and Search Strategy
A comprehensive search was conducted in PubMed, Embase, Scopus, and Web of Science on 3 February 2025. The final search strategy used a combination of keywords and Boolean operators: (‘acute pain’) AND (‘visceral pain’ OR ‘abdominal pain’) AND (‘pain assessment’ OR ‘pain measurement’) AND (‘randomized controlled trial’ OR ‘RCT’). Filters were applied to limit results to English‐language RCTs published from 1 January 2000, to the date of the final search. Reference lists of included studies and relevant reviews were also screened to undertake a reverse citation searching, but yielded no additional eligible publications.
All records from the searches were imported into Covidence, a web‐based platform for systematic review management (Veritas Health Innovation). Title and abstract screening were performed independently by two reviewers (LK, CSK). Disagreements were resolved through discussion. Articles deemed potentially relevant were retrieved in full text and assessed independently by the same two reviewers according to predefined eligibility criteria. If disagreements persisted, a third reviewer (SP) was consulted to reach a consensus. In cases of multiple publications from the same study, the most comprehensive or recent report was included, or multiple publications were merged if they provided additional pain assessment methods.
2.3.Data Extraction
Data extraction was initiated using a standardized extraction form within Covidence, adapted to the present review. Two reviewers independently extracted each article. The following data were collected:
Study characteristics: publication year, country, study population, and intervention type.
Pain‐related outcome domains: domains named by the author and/or based on specific measures, including Patient Reported Outcome Measures (PROMs); these PROMs were categorized and aggregated under their domains as recommended by COMET (Williamson et al. 2017).
Pain‐related outcome measures:
○Type of measure (PROM, Patient‐reported Experience Measure [PREM], report, etc.)
For PROMs/PREMs: tool name, type (unidimensional/multidimensional), domains assessed (intensity, quality, etc.), and rationale for use (if reported), self‐report vs. observer‐based; delivery format (e.g., paper‐based, electronic, verbal).
Context of use: inpatient vs. outpatient; type of intervention (pharmacological, procedural, etc.).
Frequency of use and diagnostic specificity of each tool.
Ability to detect change over time (e.g., pre‐ and post‐intervention scores).
Compliance and feasibility metrics, where available.
Reporting quality: clarity, consistency, and alignment with standardized guidelines (e.g., CONSORT).
2.4.Inter‐Rater Agreement
To ensure consistency and reliability in screening and extraction, all steps were performed in duplicate. Interrater agreement was assessed during the full‐text review.
2.5.Data Synthesis and Comparison
Assessment tools were mapped and summarized using narrative synthesis and descriptive statistics. Tools were classified by type (unidimensional vs. multidimensional), the domains assessed, and their frequency of use across included studies.
Temporal trends in assessment frequency were examined using linear regression with publication year as the predictor and number of repeated measurements as the outcome. Robust standard errors were applied.
The risk of bias for each included study was evaluated using the Cochrane Risk of Bias 2 tool, which assesses five domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in the measurement of outcomes, and bias in the selection of the reported result (Sterne et al. 2019). Each domain was rated as low risk of bias, some concerns, or high risk of bias, and an overall judgement was derived for each study. The assessment was performed independently by two reviewers (LK and CSK), and discrepancies were resolved through discussion.
Following peer review, we additionally classified each trial post hoc according to the diagnostic status of the population at enrolment, as either undifferentiated acute abdominal pain or a defined condition, based on the reported inclusion criteria. Outcome domains, measurement instruments, and assessment schedules were then compared between these groups. This analysis was exploratory, not pre‐specified in the PROSPERO registration, and is reported descriptively without statistical testing.
3.Results
A total of 826 studies were identified through database searches (PubMed n = 258; Embase n = 243; Scopus n = 195; Web of Science n = 130). After the removal of 381 duplicates, 445 unique records were screened by title and abstract. Eighty full‐text articles were assessed for eligibility, of which 35 were excluded: 19 lacked pain‐related outcomes, 13 included ineligible patient populations, and 3 were not randomized designs (Figure 1). The studies that did not include pain‐related outcomes either investigated conditions where pain was only one component of the symptom profile or focused on diagnostic accuracy following analgesic treatment.
Two pairs of publications reported data from the same cohorts but provided different pain assessment data and were therefore merged in the analysis (Abril Ochoa et al. 2020; Bailey, Bergeron, Gravel, and Daoust 2007; Bailey, Bergeron, Gravel, Bussières, and Bensoussan 2007; Chinn et al. 2019). The final sample included 43 RCTs, comprising 5284 patients from 15 countries across four continents. Most studies were conducted in North America (n = 23), followed by Asia/Middle East (n = 10), Europe (n = 9), and Africa (n = 1).
3.1.Study Characteristics
Study characteristics are summarized in Table 1. All studies included patients presenting with acute abdominal pain at the emergency department. Most studies included adults (n = 35/43); three of these also included participants aged < 18 years (ranging from 12 years and up, ensuring that all patients were able to read and answer relevant questions). One study included only patients aged > 65 years.
TABLE 1Study characteristics.
Author Publication year Country Intervention Sample size Study design Pain outcomes
Adult studies
D. Aghamo‐hammadi 2012 Iran Morphine 120 Parallel group, double‐blinded Opioid treatment did not affect diagnostic accuracy
O. Agodirin 2013 Nigeria Tramadol 95 Parallel group, double‐blinded Tramadol treatment did not affect diagnostic accuracy
J. Antevil 2005 USA Glycopyrrolate 39 Parallel group, double‐blinded No improvement in pain of suspected biliary tract origin in treatment with glycopyrrolate
J. Bartfield 2003 USA Intravenous fentanyl vs. Nebulised fentanyl 50 Parallel group, double‐blinded Nebulised fentanyl provided comparable analgesia to intravenous fentanyl
A. Birnbaum 2012 USA Patient‐controlled analgesia (morphine) 211 Parallel‐group, open‐label Patient‐controlled analgesia provides high treatment satisfaction and more effective analgesia than traditional treatment
A. Chang 2013 USA Hydromorphone vs. Standard care 350 Parallel group, double‐blinded 2 mg hydromorphone resulted in a higher proportion of patients declining further analgesic treatment than standard treatment after 30 min
E. Chinn 2019 USA Lidocaine vs. hydromorphone 154 Parallel group, double‐blinded Intravenous hydromorphone was superior to intravenous lidocaine for general abdominal pain
T. Deaton 2015 USA IV morphine vs. nebulised fentanyl 40 Parallel group, double‐blinded Fentanyl citrate at a dose of 2 μg/kg through a breath‐actuated nebulizer appears to be a feasible and safe alternative to intravenous morphine in patients with acute abdominal pain
J. Gallagher 2006 USA Morphine 160 Parallel group, double‐blinded Opioid treatment did not affect diagnostic accuracy
A. Giacosa 2022 Italy Boswellia serrata 49 Parallel group, double‐blinded Boswellia Serrata
provides pain relief beyond placebo in patients with acute diarrhoea
K. Kanesan 2023 Malaysia Patient‐controlled analgesia vs. bolus (opioids) 62 Parallel group, open‐label There was no significant difference in pain score reduction between PCA and intravenous bolus of morphine for the management of severe acute non‐traumatic abdominal pain in the ED. However, PCA provided more patient satisfaction and should be considered as an alternative modality of acute pain management in the ED
K. Kang 2015 Korea Morphine 219 Parallel group, double‐blinded Early pain control did not affect diagnostic accuracy
W. Kruis 2013 Germany Mesalazine 123 Parallel group, double‐blinded A daily dose of 3.0 g mesalazine may relieve pain during a symptomatic flare of uncomplicated diverticulitis
S. Lovett 2021 USA Low vs. high dose ketamine 98 Parallel group, double‐blinded No considerable difference in analgesia or adverse effect profile between 0.15 mg/kg IV ketamine and 0.30 mg/kg was detected in the short‐term treatment of acute pain in the ED
M. Mahadevan 2000 Singapore Tramadol 68 Parallel group, blinded; however, blinding was not described in detail Opioid treatment did not affect diagnostic accuracy
C. Maity 2019 India Lactobacillus 60 Parallel group, double‐blinded Bacillus coagulans
was effective in recovering from acute diarrhoea with abdominal pain and discomfort
B. McMahon 2024 USA TENS 81 Parallel‐group, sham‐controlled TENS to the abdominal wall did not provide efficient pain relief in abdominal pain
J. Miller 2015 USA Morphine vs. low‐dose ketamine 45 Parallel group, double‐blinded Low‐dose ketamine did not produce a greater reduction in NRS pain scores compared with morphine for acute pain in the emergency department
S. Motov (1) 2015 USA Ketamine vs. morphine 90 Parallel group, double‐blinded Subdissociative intravenous ketamine provides comparable analgesia to intravenous morphine
S. Motov (2) 2017 USA IV push vs. infusion of low‐dose ketamine 48 Parallel group, double‐blinded Low‐dose ketamine given as a short infusion is associated with significantly lower rates of feeling of unreality and sedation, with no difference in analgesic efficacy in comparison to intravenous push
S. Motov (3) 2017 USA Ketolac 240 Parallel group, double‐blinded Ketorolac has similar analgesic efficacy at intravenous doses of 10, 15, and 30 mg
S. Motov (4) 2019 USA Ketamine vs. morphine 60 Parallel group, double‐blinded Subdissociative ketamine provides analgesic efficacy comparable to morphine for short‐term treatment of acute pain in the geriatric ED patients, but results in higher rates of psychoperceptual adverse effects
S. Motov (5) 2019 USA Ibuprofen 225 Parallel group, double‐blinded Oral ibuprofen administered at doses of 400, 600, and 800 mg has similar analgesic efficacy for short‐term pain relief in adult patients presenting to the ED with acute pain
M. Moussa 2021 Lebanon Diclofenac 150 Parallel group, double‐blinded Intradermal sterile water injection and diclofenac were equally effective for the pain relief of acute renal colic
J. Mozafari 2020 Iran Ketamine vs. fentanyl 130 Parallel group, double‐blinded Ketamine was found to be less effective than fentanyl in controlling renal colic‐induced pain and to be associated with a higher prevalence of side effects
S. Narang 2018 India Drotaverine + paracetamol vs. paracetamol alone 252 Parallel group, double‐blinded Fixed‐dose combination of drotaverine hydrochloride (80 mg) and PCM (500 mg) is an effective and safe antispasmodic agent in abdominal pain associated with acute infectious gastroenteritis
T. Nguyen 2024 USA IV vs. nebulised ketamine 150 Parallel group, double‐blinded No difference between the administration of IV and nebulised ketamine for the short‐term treatment of moderate to severe acute pain in the ED
H. Oguzturk 2012 Turkey Tramadol/paracetamol 210 Parallel group, double‐blinded Early administration of tramadol and paracetamol provided effective pain relief in patients with non‐traumatic acute abdominal pain, and the administration did not interfere with diagnosis
V. Ojetti 2022 Italy Probiotics 119 Parallel group, double‐blinded L. reuteri
4659 did not give substantial pain relief in patients with uncomplicated diverticulitis
C. Petruzziello 2019 Italy Probiotics (
Lactobacillus reuteri
) 88 Parallel group, double‐blinded Lactobacillus reuteri
reduced abdominal pain in patients with uncomplicated diverticulitis
J. Remington‐Hobbs 2012 United Kingdom Hyoscine/hyoscine + paracetamol/paracetamol 132 Parallel group, double‐blinded Oral paracetamol is at least as effective as intravenous hyoscine butylbromide and a combination of both drugs in the management of acute undifferentiated abdominal pain presenting to the ED
B. Sin 2019 USA Morphine vs. sufentanil 60 Parallel group, double‐blinded The use of i.n. Sufentanil resulted in rapid and safe analgesia with comparable efficacy to i.v. Morphine for up to 30 min in patients who presented with acute pain in the ED
S. Thomas 2003 USA Morphine 74 Parallel group, double‐blinded Opioid treatment did not affect diagnostic accuracy
C. Yildirim 2024 Turkey Hyoscine‐n‐butylbromide 50 Parallel group, double‐blinded No clinical or statistical difference in analgesic effect
C. Zhu 2017 China Hyoscine butylbromide vs. anisodamine 299 Parallel group, double‐blinded Hyoscine butylbromide was non‐inferior to anisodamine in pain relief of patients with acute gastric or intestinal spasm‐like pain
Paediatric studies
B. Bailey 2007 Canada Morphine 90 Parallel group, double‐blinded Only the visual analogue scale and colour analogue scale had a limit of agreement less than the limit of acceptability of ±20 mm
G. Cozzi 2019 Italy Ketorolac/tramadol/paracetamol 210 Parallel group, patients were blinded, but physicians were not Similar analgesic effect in all groups
R. Green 2005 Canada Morphine 108 Parallel group, double‐blinded Opioid treatment did not affect diagnostic accuracy
J. Kang 2021 China Modified endoscopic retrograde appendicitis therapy vs. antibiotics 94 Parallel group, open label Modified Endoscopic Retrograde Appendicitis Therapy provides a new alternative therapeutic option for children with uncomplicated acute appendicitis, especially for families who are reluctant to undergo an appendectomy
M. Kim 2002 USA Morphine 60 Parallel group, double‐blinded Opioid treatment did not affect diagnostic accuracy
H. Kokki 2005 Finland Oxycodone 63 Parallel group, double‐blinded Early administration of buccal oxycodone provides significant pain relief in children with acute abdominal pain
N. Poonai 2020 Canada Hyoscine 236 Parallel group, double‐blinded Hyoscine butylbromide provided equal pain relief as acetaminophen in children with acute pain
K. Quinn 2018 USA Ketamine vs. fentanyl 22 Parallel group, double‐blinded Intranasal ketamine was found to be inferior to intranasal fentanyl in relieving pain at 10 min and was found to have significantly greater rates of sedation and dizziness
Eight of 43 studies focused exclusively on paediatric populations with an age range of 1–18 years.
Sample sizes ranged from 39 to 350 participants (median = 98) in adult studies and 22–236 participants in paediatric studies (median 92). Inclusion and exclusion criteria are summarized in Table S1.
All eligible studies were interventional, enrolling patients directly from Emergency Departments. Interventions in the adult studies primarily involved analgesic treatments (n = 29/35) (Aghamohammadi et al. 2012; Agodirin et al. 2013; Antevil et al. 2005; Bartfield et al. 2003; Birnbaum et al. 2012; Chang et al. 2013; Chinn et al. 2019; Deaton et al. 2015; Gallagher et al. 2006; Kanesan and Rahman 2023; Kang et al. 2015; Lovett et al. 2021; Mahadevan and Graff 2000; Miller et al. 2015; Motov et al. 2015; Motov, Mai, et al. 2017; Motov, Yasavolian, et al. 2017; Motov, Masoudi, et al. 2019; Motov, Mann, et al. 2019; Moussa et al. 2021; Mozafari et al. 2020; Narang and Koli 2018; Nguyen et al. 2024; Oguzturk et al. 2012; Remington‐Hobbs et al. 2012; Sin et al. 2019; Thomas et al. 2003; Yildirim and Pamukçu Günaydin 2024; Zhu et al. 2017), procedural interventions (n = 1/35) (McMahon et al. 2024), or disease‐specific medical treatments (n = 5/35) (Giacosa et al. 2022; Kruis et al. 2013; Maity and Gupta 2019; Ojetti et al. 2022; Petruzziello et al. 2019). Analgesic interventions included antispasmodics, non‐opioid analgesics, ketamine, and opioids. The procedural intervention was transcutaneous electrical nerve stimulation. In paediatric studies, interventions included analgesic treatment (n = 7/8) (Bailey, Bergeron, Gravel, and Daoust 2007; Bailey, Bergeron, Gravel, Bussières, and Bensoussan 2007; Cozzi et al. 2019; Green et al. 2005; Kim et al. 2002; Kokki et al. 2005; Poonai et al. 2020; Quinn et al. 2018) and procedural interventions (n = 1/8) (Kang et al. 2021). Analgesic treatments were similar in paediatric and adult studies. The sole intervention was endoscopic treatment of appendicitis.
All included studies used pain assessment methods, and the different pain domains assessed are summarized in Table 2 and Figure 2.
TABLE 2Assessment of pain domainsa.
Author Pain intensity Frequency Pain relief Rescue analgesic/total dose Adverse effects Pattern Duration Location Physical examination Quality of life
Adult studies
D. Aghamo‐hammadi Numeric Rating Scale 0–10 At baseline and after 25 min No side effects were reported Abdominal tenderness, abdominal rebound
O. Agodirin Numeric Rating Scale 0–10 At baseline and after 15–20 min Not reported
J. Antevil Visual Analogue Scale 0–100 mm At baseline and after 20 min Rebound tenderness, involuntary guarding, and pain migration
J. Bartfield Visual Analogue Scale 0–100 mm At baseline, after 15 and 30 min
A. Birnbaum Visual Analogue Scale 0–10 At baseline, after 30, 60, 90, and 120 min Patient satisfaction Total dose Sedation, hypotension, oxygen desaturation
A. Chang Numeric Rating Scale 0–10 At baseline, after 15, 30, 45, 60, 90, and 120 min Declined further analgesics, achieved > 50% reduction in NRS, achieved NRS ≤ 3 in 30 min, complete resolution of pain in 30 min Bradycardia, hypotension, pruritus, nausea, vomiting
E. Chinn Numeric Rating Scale 0–10 At baseline, after 15, 30, 45, 60, 90, and 120 min Patient satisfaction Rescue analgesics Dizziness, drowsiness, headache, nausea, pruritus Yes
T. Deaton Visual Analogue Scale 0–100 mm At baseline, after 10, 20, 30, and 40 min Patient satisfaction, physician satisfaction Rescue analgesics
J. Gallagher Visual Analogue Scale 0–100 mm At baseline and after 15 min
A. Giacosa Visual Analogue Scale 0–10 At baseline and at day 6 Abdominal distension
K. Kanesan Visual Analogue Scale 0–10 At baseline, after 30, 60, and 120 min Experience of pain relief
Patient satisfaction
Total dose No significant adverse effects were reported
K. Kang Visual Analogue Scale 0–10 cm At baseline and after 30 min Not reported
W. Kruis Visual Analogue Scale 0–100 mm, A 4‐point pain intensity Likert scale (no, slight, moderate, severe, most severe) At baseline and daily for 6 weeks 4‐point treatment efficacy Likert scale (ineffective, moderately effective, effective, very effective) Headache, diarrhoea Pain frequency 0–100 mm Yes
S. Lovett Numeric Rating Scale 0–10 At baseline, after 15, 30, and 60 min Patient satisfaction Total dose, rescue analgesics Fatigue, dizziness, headache, unreal feeling, hearing changes, vision changes, mood alterations, discomfort, hallucination Yes
M. Mahadevan Visual Analogue Scale 0–100 mm At baseline, after 30, and 60 min Yes Percussion tenderness, light/deep tenderness, rebound tenderness, cough tenderness
C. Maity Universal Pain Assessment Scale (mild, moderate, severe) At baseline, after 24, 48, and 120 h Not reported Not reported
B. McMahon Numeric Rating Scale 0–10 At baseline and after 30 min Analgesics prior to admission, rescue analgesics No adverse effects of treatment reported Yes
J. Miller Numeric Rating Scale 0–10 At baseline, after 15, 30, 45, 60, 75, 90, 105, and 120 min Patient satisfaction Total dose Nausea, vomiting, oxygen de‐saturation, hallucination
S. Motov (1) Numeric Rating Scale 0–10 At baseline, after 5 min, after 10, 20, 40, 60, 80, 100, and 120 min Complete resolution of pain, reduction of NRS ≥ 3 Rescue analgesics Dis‐orientation, dizziness, mood changes, nausea
S. Motov (2) Numeric Rating Scale 0–10 At baseline, after 15, 30, 60, 90, and 120 min Rescue analgesics Fatigue, dizziness, headache, unreal feeling, vision changes, mood alterations, discomfort, hallucination
S. Motov (3) Numeric Rating Scale 0–10 At baseline, after 5, 15, 30, 60, 90, and 120 min Rescue analgesics Dizziness, nausea, headache, pruritus, flushing
S. Motov (4) Numeric Rating Scale 0–10 At baseline, after 15, 30, 60, 90, and 120 min Complete resolution of pain, reduction of pain by NRS ≥ 3 Rescue analgesics Fatigue, dizziness, headache, unreal feeling, hearing changes, vision changes, mood alterations, discomfort, hallucination
S. Motov (5) Numeric Rating Scale 0–10 At baseline and after 60 min Rescue analgesics No adverse effects reported
M. Moussa Visual Analogue Scale 0–10 cm At baseline, after 30, 45, and 60 min Rescue analgesics Nausea, vomiting, epigastric pain, and pain at the injection site
J. Mozafari Visual Analogue Scale 0–10 cm At baseline, after 5, 15, and 30 min Rescue analgesics Nausea, vomiting, headache, dizziness, agitation
S. Narang Visual Analogue Scale 0–100 mm, A 4‐point pain intensity Likert scale At baseline, after 15, 30, 60, 90, and 120 min, after 24, 48, and 72 h Global improvement score (patient), global improvement score (physician) Dizziness, vomiting, nausea, headache, weakness, sleepiness, periorbital burning, body ache Pain pattern
T. Nguyen Numeric Rating Scale 0–10 At baseline, after 15, 30, 60, 90, and 120 min Rescue analgesics Sedation, restlessness, dizziness, an unreal feeling
H. Oguzturk Visual Analogue Scale 0–100 mm At baseline, after 20 and 40 min Nausea, vomiting, dizziness Rebound tenderness, rigidity
V. Ojetti Visual Analogue Scale 0–10 cm At baseline and daily for 10 days Not reported
C. Petruzziello Visual Analogue Scale 0–10 cm At baseline and daily for 10 days No adverse effects reported
J. Remington‐Hobbs Visual Analogue Scale 0–100 mm At baseline, after 30, 60, and 180 min Rescue analgesics Blurred vision, dizziness, drowsiness, dry mouth, palpitations, spaced out, nausea
B. Sin Numeric Rating Scale 0–10 At baseline, after 5, 10, 20, and 30 min Patient satisfaction Rescue analgesics Nausea, vomiting, dizziness, drowsiness, oxygen desaturation
S. Thomas Visual Analogue Scale 0–10 cm At baseline and after 60 min Yes Signs of peritoneal irritation
C. Yildirim Visual Analogue Scale 0–100 mm At baseline, after 30, and 60 min Rescue analgesics Dizziness
C. Zhu Numeric Rating Scale 0–10 At baseline, after 10, 20, 30, 60, and 120 min Patient satisfaction Rescue analgesics Thirst, dry mouth, nodal arrhythmia, hernia, eventration, and ileus
Paediatric studies
B. Bailey Visual Analogue Scale 0–100 mm, Colour Analogue Scale, Wong‐Baker FACES, Numeric Rating Scale At baseline and after 30 min Rescue analgesics Pruritus, nausea, vomiting, drowsiness, dizziness Yes Yes Involuntary guarding, rebound tenderness
G. Cozzi Numeric Rating Scale 0–10, Wong Baker FACES At baseline, after 30, 60, and 120 min Nausea, vomiting, dizziness, epigastric pain
R. Green The Colour Analogue Scale At baseline and after 15 min Not reported Right lower quadrant tenderness, involuntary/voluntary guarding
J. Kang At the end of the study Symptom resolution Not reported Yes
M. Kim Visual Analogue Scale 0–10 At baseline and after 30 min Nausea, pruritus Palpatory tenderness area, percussion tenderness area
H. Kokki Visual Analogue Scale 0–10 cm At baseline and every 30 min for 3.5 h Headache, urticaria Abdominal guarding, right lower quadrant pain, migration of pain, rebound tenderness
N. Poonai Visual Analogue Scale 0–100 mm At baseline, after 15, 30, 45, 60, and 80 min Rescue analgesics Nausea, dizziness, dry mouth, photo‐sensitivity, vomiting, constipation, dry skin, palpitations, diarrhoea, sweating, drowsiness, headache, urticaria
K. Quinn Numeric Rating Scale 0–10, Wong Baker FACES At baseline, after 10, 20, 30, and 60 min Analgesics before enrolment, rescue analgesics Dizziness, sedation
aAs no studies examined psychological features or pain interference, this part has been left out of the table.
Trend analysis suggested an increase in assessment frequency over time (β = 0.11 per year, p = 0.032) when excluding an extreme outlier with daily measurements for > 1 month, indicating that more recent studies tend to include a higher number of repeated pain measurements. Studies published after 2013 typically reported 4–7 repeated assessments, whereas studies from the early 2000s commonly included only 2–3 (Figure 3).
3.2.Outcome Domains According to the Underlying Condition
Twenty‐nine of the 43 (67%) trials enrolled patients with undifferentiated acute abdominal pain, recruited on the basis of the symptom and its severity rather than an established diagnosis, while 14 (33%) trials enrolled patients with a defined condition: acute diarrhoea or gastroenteritis (n = 4), suspected or confirmed appendicitis (n = 4), acute uncomplicated diverticulitis (n = 3), renal colic (n = 2), and suspected biliary disease (n = 1). The classification of each trial is reported in Table S2. Ten of the trials classified as undifferentiated recruited patients with acute pain at mixed anatomical sites, with abdominal pain as one of several eligible locations. Pain intensity was assessed in 42 of the 43 (98%) trials across all diagnostic groups, the exception of a paediatric trial of endoscopic treatment for appendicitis that reported symptom resolution only. Analgesic use was reported in 18 of 29 (62%) trials of undifferentiated pain compared with 4 of 14 (29%) condition‐specific trials, and pain relief or treatment satisfaction in 11 of 29 (40%) compared with 3 of 14 (21%). Of the 10 trials that recorded physical examination findings, 9 (90%) enrolled patients in whom a surgical diagnosis was under consideration, and the temporal pattern of pain was assessed only in one trial of diverticulitis and one of infectious diarrhoea (20%). The assessment schedule separated the groups more clearly than the domains did, in that trials of undifferentiated pain followed patients over minutes to two hours after a single analgesic intervention, whereas trials in diverticulitis and acute diarrhoea followed pain daily over days to weeks. The NRS was the primary instrument in 17 of 29 (59%) trials of undifferentiated pain and in none of the condition‐specific trials, which used the VAS or a verbal Likert scale. No trial in any diagnostic group assessed pain interference, emotional distress or quality of life.
3.3.Adult Studies
3.3.1.Number of Pain‐Related Domains
Most adult trials assessed three pain‐related domains (n = 15/35), while only 12 studies out of 35 assessed more than three domains (Figure 4). Over time, there has been a shift from one single domain (pain intensity) towards multi‐domain capture (e.g., pain relief, rescue analgesia, adverse effects) (β = 0.05 per year, p = 0.048).
3.3.2.Pain Intensity Domain
All adult studies reported pain intensity outcomes. The most frequently used instrument to assess pain intensity was the VAS (n = 19, 54%) (Antevil et al. 2005; Bartfield et al. 2003; Birnbaum et al. 2012; Deaton et al. 2015; Gallagher et al. 2006; Giacosa et al. 2022; Kanesan and Rahman 2023; Kang et al. 2015; Kruis et al. 2013; Mahadevan and Graff 2000; Moussa et al. 2021; Mozafari et al. 2020; Narang and Koli 2018; Oguzturk et al. 2012; Ojetti et al. 2022; Petruzziello et al. 2019; Remington‐Hobbs et al. 2012; Thomas et al. 2003; Yildirim and Pamukçu Günaydin 2024), followed by the NRS (n = 15, 43%) (Aghamohammadi et al. 2012; Agodirin et al. 2013; Chang et al. 2013; Chinn et al. 2019; Lovett et al. 2021; McMahon et al. 2024; Miller et al. 2015; Motov et al. 2015; Motov, Mai, et al. 2017; Motov, Yasavolian, et al. 2017; Motov, Masoudi, et al. 2019; Motov, Mann, et al. 2019; Nguyen et al. 2024; Sin et al. 2019; Zhu et al. 2017). Three studies out of 35 used Likert scales, where two employed both VAS and a Likert scale (Kruis et al. 2013; Narang and Koli 2018), and one study used only a Likert scale (Maity and Gupta 2019).
All studies evaluated pain intensity at rest; none during activity.
In 83% of adult studies (n = 29/35), pain intensity was assessed within the first two hours after treatment (Aghamohammadi et al. 2012; Agodirin et al. 2013; Antevil et al. 2005; Bartfield et al. 2003; Birnbaum et al. 2012; Chang et al. 2013; Chinn et al. 2019; Deaton et al. 2015; Gallagher et al. 2006; Kanesan and Rahman 2023; Kang et al. 2015; Lovett et al. 2021; Mahadevan and Graff 2000; Maity and Gupta 2019; McMahon et al. 2024; Miller et al. 2015; Motov et al. 2015; Motov, Mai, et al. 2017; Motov, Yasavolian, et al. 2017; Motov, Masoudi, et al. 2019; Motov, Mann, et al. 2019; Moussa et al. 2021; Mozafari et al. 2020; Nguyen et al. 2024; Oguzturk et al. 2012; Sin et al. 2019; Thomas et al. 2003; Yildirim and Pamukçu Günaydin 2024; Zhu et al. 2017), while 6 out of 35 assessed pain for ≥ 72 h (Giacosa et al. 2022; Kruis et al. 2013; Maity and Gupta 2019; Narang and Koli 2018; Ojetti et al. 2022; Petruzziello et al. 2019). Long‐duration follow‐ups employed Likert scales (n = 1, 3%) (Maity and Gupta 2019), VAS (n = 3, 9%) (Giacosa et al. 2022; Ojetti et al. 2022; Petruzziello et al. 2019), or both (n = 2, 6%) (Kruis et al. 2013; Narang and Koli 2018).
Pain intensity was assessed a median of four times per study, with Likert scales being used more frequently than NRS/VAS (mean = 18.7 vs. 4.7 assessments).
A temporal trend for the use of pain intensity measurement tools was observed: prior to 2010, VAS was predominant (VAS = 8; NRS = 1 of 9), while from approximately 2011 onward, NRS use gradually increased and became dominant in studies published after 2015 (NRS = 10; VAS = 9 of 20) (Figure 5).
3.3.3.Analgesic Domain
3.3.3.1.Rescue Analgesics and Total Analgesic Use
Nineteen studies assessed analgesic use. Four of 35 studies reported the mean dose of analgesics administered (Birnbaum et al. 2012; Kanesan and Rahman 2023; Lovett et al. 2021; Miller et al. 2015); 16 reported the use of rescue analgesia (Chinn et al. 2019; Deaton et al. 2015; Lovett et al. 2021; McMahon et al. 2024; Motov et al. 2015; Motov, Mai, et al. 2017; Motov, Yasavolian, et al. 2017; Motov, Masoudi, et al. 2019; Motov, Mann, et al. 2019; Moussa et al. 2021; Mozafari et al. 2020; Nguyen et al. 2024; Remington‐Hobbs et al. 2012; Sin et al. 2019; Yildirim and Pamukçu Günaydin 2024; Zhu et al. 2017).
Twenty‐three of 35 adult trials excluded patients who had received analgesics prior to enrollment: 16 excluded all pre‐treatment analgesics, and 7 excluded only opioid use. Of the remaining 12 studies, only one reported whether pre‐inclusion analgesia had been administered (McMahon et al. 2024).
3.3.3.2.Treatment Satisfaction
Eight studies reported treatment satisfaction (Birnbaum et al. 2012; Chinn et al. 2019; Deaton et al. 2015; Kanesan and Rahman 2023; Lovett et al. 2021; Miller et al. 2015; Sin et al. 2019; Zhu et al. 2017). One study additionally evaluated physician satisfaction (Deaton et al. 2015). Not all studies provided information on the method of assessment; some asked whether patients were satisfied with the treatment effect, and some asked whether patients would prefer the same analgesic treatment for future reference. No study reported the use of validated instruments or questions for this assessment.
3.3.3.3.Adverse Drug Effects
28/35 studies assessed treatment side effects or adverse effects (Aghamohammadi et al. 2012; Agodirin et al. 2013; Birnbaum et al. 2012; Chang et al. 2013; Chinn et al. 2019; Kanesan and Rahman 2023; Kang et al. 2015; Kruis et al. 2013; Lovett et al. 2021; Maity and Gupta 2019; McMahon et al. 2024; Miller et al. 2015; Motov et al. 2015; Motov, Mai, et al. 2017; Motov, Yasavolian, et al. 2017; Motov, Masoudi, et al. 2019; Motov, Mann, et al. 2019; Moussa et al. 2021; Mozafari et al. 2020; Narang and Koli 2018; Nguyen et al. 2024; Oguzturk et al. 2012; Ojetti et al. 2022; Petruzziello et al. 2019; Remington‐Hobbs et al. 2012; Sin et al. 2019; Yildirim and Pamukçu Günaydin 2024; Zhu et al. 2017), four studies claimed to assess side effects or adverse effects, but did not report either in the result section (Agodirin et al. 2013; Kang et al. 2015; Maity and Gupta 2019; Ojetti et al. 2022). Studies typically either used open‐ended questions or did not specify the method for assessing side effects. No measurement instrument for adverse events/side effects was mentioned in any of the studies.
3.3.4.Pain Pattern, Duration, and Location Domains
Two adult studies assessed pain pattern (constant vs. intermittent or frequency of pain) through a pain diary (Kruis et al. 2013; Narang and Koli 2018), and three reported pain duration or time to resolution (Chinn et al. 2019; Kruis et al. 2013; Lovett et al. 2021) but did not specify how the duration was assessed. Three adult studies (Mahadevan and Graff 2000; McMahon et al. 2024; Thomas et al. 2003) reported pain location.
3.3.5.Physical Examination Domain
Six of the 35 adult studies (Aghamohammadi et al. 2012; Antevil et al. 2005; Giacosa et al. 2022; Mahadevan and Graff 2000; Oguzturk et al. 2012; Thomas et al. 2003) recorded objective findings, including rebound tenderness, voluntary or involuntary guarding, cough tenderness, and abdominal distension. The findings were typically predefined, but no measurement instrument was mentioned.
3.3.6.Pain Interference, Psychological Outcomes, and Quality of Life Domains
No study assessed how pain interfered with physical function (e.g., mobilization). Quality of life was listed as an outcome in one adult study, but the assessment method was not clearly defined. From the results section, it was indicated that the quality of life was based on the presence of constipation, diarrhoea, or blood/mucus in stool, rather than functional effects (Maity and Gupta 2019). No study reported psychological outcomes.
3.4.Paediatric Studies
3.4.1.Number of Pain‐Related Domains
Paediatric studies evaluated 2–6 domains. No temporal trend in domains assessed was seen in paediatric studies (β = −0.05 per year, p = 0.232).
3.4.2.Pain Intensity Domain
Among paediatric studies, all but one study reported pain intensity (n = 7/8); the remaining study reported only pain duration and resolution (Kang et al. 2021). The studies generally used age‐appropriate instruments such as the Wong–Baker FACES Pain Scale or the Colour Analogue Scale (n = 4/8) (Bailey, Bergeron, Gravel, and Daoust 2007; Cozzi et al. 2019; Green et al. 2005; Quinn et al. 2018). One paediatric trial compared four different intensity tools (VAS, FACES, NRS, and Colour Analogue Scale) (Bailey, Bergeron, Gravel, and Daoust 2007). Three studies used only the VAS, and the lowest inclusion age in these studies was 4 years of age (Kim et al. 2002; Kokki et al. 2005; Poonai et al. 2020).
All studies assessed pain intensity at rest.
In the paediatric studies, 5 out of 8 studies assessed pain within the first two hours after treatment and no studies had long‐duration follow‐ups beyond 72 h.
3.4.3.Analgesic Domain
3.4.3.1.Rescue Analgesics and Total Analgesic Use
No studies reported the mean dose of analgesics administered; three of eight studies reported use of rescue analgesics (Bailey, Bergeron, Gravel, Bussières, and Bensoussan 2007; Poonai et al. 2020; Quinn et al. 2018).
Five of the studies excluded patients who had received analgesics prior to enrollment, where two excluded all analgesics and three only excluded opioid treatment. One of the remaining three studies reported whether analgesia had been administered before inclusion.
3.4.3.2.Adverse Drug Effects
All studies assessed treatment side effects and/or adverse effects, but two studies did not report the results (Green et al. 2005; Kang et al. 2021). No paediatric study reported treatment satisfaction.
3.4.4.Pain Pattern, Duration, and Location Domains
Two paediatric studies reported pain duration without specifying the mode of assessment (Bailey, Bergeron, Gravel, Bussières, and Bensoussan 2007; Kang et al. 2021). No study reported pain pattern. One paediatric study (Bailey, Bergeron, Gravel, Bussières, and Bensoussan 2007) reported pain location from a standardized objective abdominal assessment rather than patient report.
3.4.5.Physical Examination Domain
Four studies (Bailey, Bergeron, Gravel, Bussières, and Bensoussan 2007; Green et al. 2005; Kim et al. 2002; Kokki et al. 2005) recorded objective findings similar to the findings reported in adult studies.
3.4.6.Pain Interference, Psychological Outcomes, and Quality of Life Domains
Pain interference, psychological function, and quality of life were not assessed in any of the paediatric studies.
3.5.Risk of Bias
Risk of bias was evaluated using the Cochrane Risk of Bias 2 tool. Most studies were judged to have low risk of bias in domains related to randomization, deviations from intended interventions, and outcome measurement (Table 3). However, concerns were frequent for missing outcome data and especially for selective reporting, where most studies were rated as having some concerns.
TABLE 3Risk of bias assessment.
Author Bias from the randomization process Bias due to deviations from intended interventions Bias due to missing outcome data Bias in the measurement of the outcomes Bias in the selection of the reported result Overall risk of bias
Adult studies
D. Aghamohammadi Low Low Low Low Some concerns Some concerns
O. Agodirin Low Low Low Low High High
J. Antevil Low Low Low Low Some concerns Some concerns
J. Bartfield Low Low Low Some concerns Low Some concerns
A. Birnbaum Low Low Low Some concerns Low Some concerns
A. Chang Low Low Low Some concerns Low Some concerns
E. Chinn Low Low Low Low Low Low
T. Deaton Low Low Low Low Some concerns Some concerns
J. Gallagher Low Low Low Low Some concerns Some concerns
A. Giacosa Some concerns Low Low Low Low Some concerns
K. Kanesan Low Low Low Some concerns Some concerns Some concerns
K. Kang Low Low Low Low High High
W. Kruis Low Low Low Some concerns Low Some concerns
S. Lovett Low Low Low Low Low Low
M. Mahadevan Low Low Low Low Some concerns Some concerns
C. Maity Low Low Low Low High High
B. McMahon Low Low Low Low Some concerns Some concerns
J. Miller Some concerns Low Low Low Some concerns Some concerns
S. Motov (1) Low Low Low Low Low Low
S. Motov (2) Low Low Low Low Low Low
S. Motov (3) Low Low Low Low Some concerns Some concerns
S. Motov (4) Low Low Low Low Low Low
S. Motov (5) Low Low Low Low Some concerns Some concerns
M. Moussa Low Low Low Low Some concerns Some concerns
J. Mozafari Low Low Low Low Some concerns Some concerns
S. Narang Low Low Low Low Some concerns Some concerns
T. Nguyen Low Low Low Low Low Low
H. Oguzturk Low Low Low Low Some concerns Some concerns
V. Ojetti Low Low Low Low High High
C. Petruzziello Low Low Low Low Some concerns Some concerns
J. Remington‐Hobbs Low Low Low Low Some concerns Some concerns
B. Sin Low Low Low Low Low Low
S. Thomas Low Low Low Low Some concerns Some concerns
C. Yildirim Low Low Low Low Low Low
C. Zhu Low Low Low Low Low Low
Paediatric studies
B. Bailey Low Low Low Low Some concerns Some concerns
G. Cozzi Low Low Low Some concerns Low Some concerns
R. Green Low Low Low Low High High
J. Kang Low Low Low Low High High
M. Kim Low Low Low Low Some concerns Some concerns
H. Kokki Low Low Low Low Some concerns Some concerns
N. Poonai Low Low Low Low Low Low
K. Quinn Low Low Low Low Low Low
Common issues included the absence of trial preregistration and unblinded study designs. Four of 35 adult studies were rated as high risk of bias in one or more domains (Agodirin et al. 2013; Kang et al. 2015; Maity and Gupta 2019; Ojetti et al. 2022), primarily due to missing reports of predefined outcomes. Twenty‐two studies had some concerns in one or more domains (Aghamohammadi et al. 2012; Antevil et al. 2005; Bartfield et al. 2003; Birnbaum et al. 2012; Chang et al. 2013; Deaton et al. 2015; Gallagher et al. 2006; Giacosa et al. 2022; Kanesan and Rahman 2023; Kruis et al. 2013; Mahadevan and Graff 2000; McMahon et al. 2024; Miller et al. 2015; Motov, Yasavolian, et al. 2017; Motov, Masoudi, et al. 2019; Moussa et al. 2021; Mozafari et al. 2020; Narang and Koli 2018; Oguzturk et al. 2012; Petruzziello et al. 2019; Remington‐Hobbs et al. 2012; Thomas et al. 2003).
Two of the eight paediatric studies were rated as high risk of bias in one or more domains (Green et al. 2005; Kang et al. 2021), primarily due to missing reports of predefined outcomes. Four studies had some concerns in one or more domains (Bailey, Bergeron, Gravel, Bussières, and Bensoussan 2007; Cozzi et al. 2019; Kim et al. 2002; Kokki et al. 2005).
Overall, the evidence base for evaluating current practice in acute abdominal pain assessment was considered to be of acceptable methodological quality, with predominantly low to moderate risk of bias.
Studies with a lower risk of bias more frequently included clinically relevant effect measures such as patient satisfaction and responder‐based definitions of pain relief. In contrast, high‐risk of bias studies rarely assessed pain relief, and instead tended to include nonspecific objective abdominal signs (e.g., guarding, rebound tenderness) which were not captured in low‐risk studies.
4.Discussion
This systematic review identified 43 randomized controlled trials including 5284 patients with acute abdominal pain. Of these, eight studies (883 patients) focused solely on paediatric patients. Almost all studies assessed pain intensity, most commonly using the Visual Analogue Scale or the Numeric Rating Scale. Over time, a gradual shift was observed from VAS to NRS as the preferred tool for evaluating pain intensity, and there was a trend towards more frequent measures. Pain was typically assessed within the first two hours after treatment, and only a minority of studies reported pain beyond 72 h. Measures of pain interference, psychological domains, or quality of life were entirely omitted. Also, multidimensional assessment methods were virtually never used. Although most studies demonstrated low to moderate risk of bias, selective reporting, and lack of preregistration were frequent concerns.
4.1.Interpretation and Implications
The findings of the review suggest that research related to interventions for acute abdominal pain has predominantly focused on unidimensional pain intensity measures. This focus is not unexpected, given the acute setting and short follow‐up periods of most included trials. However, while such tools are simple, quick, and familiar to clinicians, they capture only one aspect of the pain experience (Crisman et al. 2024). Acute abdominal pain is a complex experience that includes sensory, psychological, cognitive, and autonomic factors (Kuner and Kuner 2021). Limiting assessment to intensity alone may therefore restrict interpretability of treatment effects and mask clinically meaningful differences in patient outcomes, particularly in studies aiming to evaluate outcomes beyond immediate analgesic relief (Crombez et al. 2023).
These tools were not specifically validated for visceral pain or in the context of acute abdominal pain (Hjermstad et al. 2011). The near absence of multidimensional tools (Crisman et al. 2024), such as the McGill Pain Questionnaire (Melzack 1975) or the Brief Pain Inventory (MD Anderson Cancer Center), suggests that clinical trials in this field continue to rely on a relatively narrow assessment of pain.
The INTEGRATE‐pain initiative recommends inclusion of pain (intensity and interference), physical function, and quality of life as core outcome domains in acute pain trials (Bova et al. 2023). Similarly, IMMPACT and PedIMMPACT recommendations propose broader domain coverage, including pain relief, onset and duration of analgesic effects, patient satisfaction, adverse effects, and emotional response (Cooper et al. 2016; McGrath et al. 2008). Few of the included studies incorporated these domains, reflecting a gap between recommended and applied outcome assessment.
Outcome assessment in acute abdominal pain is substantially less comprehensive than in chronic abdominal pain research, particularly chronic pancreatitis, where pain characteristics, psychological function, and quality of life are routinely considered (Teo et al. 2016).
The appropriateness of pain domains might depend on the clinical context and time frame of assessment. In emergency department settings with short observation periods, rapid and simple measures such as pain intensity and analgesic use may be most feasible to capture immediate treatment effects. However, if the situation of a patient is stabilized, domains such as physical functioning, quality of life, and psychological function should still be assessed in the acute phase, as recommended for acute pain in general (Bova et al. 2023).
Although paediatric trials tended to include slightly more pain‐related domains than adult trials, they still relied almost exclusively on pain intensity scales and short‐term outcomes. Despite well‐recognized developmental differences in pain communication, no study incorporated paediatric PROMs beyond pain intensity (e.g., functional interference or emotional distress).
The trials differed in whether a diagnosis had been established at enrolment, and this was reflected in what was measured. In undifferentiated abdominal pain, where the trials asked whether a single analgesic dose relieves pain in the emergency department, the domains assessed were pain intensity, analgesic use, pain relief, and adverse effects, all captured within two hours. In trials of a defined condition such as diverticulitis or infectious diarrhoea, where treatment targets the disease rather than the pain, pain intensity was followed daily for days or weeks alongside the temporal pattern of symptoms. Physical examination findings were recorded almost exclusively in trials where a surgical diagnosis was under consideration, which reflects the longstanding concern that analgesia masks diagnostic signs rather than an interest in pain experience. The domains shared across conditions were therefore those tied to the immediate treatment of pain, whereas the underlying condition determined the timeframe of follow‐up and whether examination findings were recorded.
Future trials should adopt a context‐specific approach to outcome selection, where domains are aligned with both the clinical purpose and the time frame of assessment.
To address the identified gaps, a Core Outcome Set (COS) for acute abdominal pain should be developed to establish which domains and measures should be consistently assessed across trials. This process should engage all relevant stakeholders—including clinicians, researchers, regulators, and patient representatives—to ensure that the selected outcomes reflect both scientific rigour and patient priorities.
4.2.Temporal Trends and Clinical Considerations
The observed shift from VAS to NRS over the past decade mirrors developments in other pain settings. NRS is generally preferred for its simplicity, ease of administration, and lower cognitive demand (Firdous et al. 2021; Hjermstad et al. 2011). One study in this review compared the psychometric properties of scales in children and found that the VAS and NRS had wide limits of agreement, thereby precluding their use interchangeably (Bailey, Bergeron, Gravel, and Daoust 2007). A previous review comparing VAS and NRS, however, showed that the two correlate, except for a few studies where VAS scores were systematically higher than NRS scores (Hjermstad et al. 2011).
Most studies assessed pain only during the initial hours after treatment, reflecting a focus on immediate analgesic efficacy rather than sustained relief, side effects, functional, and psychological recovery. The lack of long‐term follow‐up limits understanding of whether early pain reduction translates into better patient outcomes, such as earlier mobilization, greater diagnostic certainty, or improved satisfaction (Cooper et al. 2016).
These observations should be interpreted with caution, as we did not account for factors that may influence the choice of outcome measure and assessment frequency, including study rationale and design.
4.3.Strengths and Limitations
This review followed PRISMA 2020 guidelines, used duplicate screening and extraction, and applied a validated risk‐of‐bias tool. Inclusion was limited to RCTs, increasing methodological robustness. However, potential limitations include restriction to English‐language publications and possible publication bias towards positive findings. Because the included trials varied widely in diagnosis, setting, timing of pain assessment, and choice of pain measures, statistical pooling was not feasible. We therefore relied on descriptive synthesis, although this approach may mask more subtle patterns in how pain is assessed across studies.
Our comparison of outcome domains according to the underlying condition was exploratory and performed post hoc. The condition‐specific groups were small, ranging from one to four trials, and diagnosis was closely tied to intervention type, follow‐up duration, and publication year, so the differences we describe cannot be attributed to the underlying condition alone. A further source of heterogeneity is that 10 of the included trials recruited patients with acute pain at mixed anatomical sites, with abdominal pain as one of several eligible locations, so their outcome assessment was not designed for abdominal pain specifically.
The gaps identified here resemble those in other acute pain settings, such as acute postoperative pain (Bigalke et al. 2021; Maeßen et al. 2021), where the need for a COS has led to the recent development of a COS of domains (Pogatzki‐Zahn et al. 2021) and, respectively, PROMs (Pogatzki‐Zahn et al. 2025).
Measurement instruments used in trials and clinical practice for abdominal pain–specific assessments should be chosen based on COSMIN recommendations, including construct validity and responsiveness in this unique pain setting (Bova et al. 2023; Cooper et al. 2016; Williamson et al. 2017).
According to COSMIN guidance, content validity is the most important measurement property and should be demonstrated before evaluating other properties such as reliability or responsiveness (Gagnier et al. 2021).
Taken together, our findings highlight a misalignment between what is commonly measured in acute abdominal pain trials and what patients, clinicians, guidelines, and regulators increasingly consider to be necessary for a more comprehensive assessment of pain and what constitutes meaningful changes. At the moment, a COS for acute pain should be used to assess the most relevant outcomes in clinical acute abdominal pain trials and clinical practice (Bova et al. 2023). However, because abdominal pain is a particular entity, the development of a core outcome set specific to different types of acute abdominal pain would promote standardization across trials and strengthen the interpretability of future evidence.
Author Contributions
L.K., N.J., S.S.O., J.W., A.M.D., S.P., and E.P.‐Z. designed the study. L.K. and C.S.K. performed the data extraction; S.P. and N.J. were available for resolving any disagreements. L.K. and E.P.‐Z. analysed the data. L.K. had a primary role in preparing the manuscript, which E.P.‐Z., A.M.D., and S.P. edited. All authors have approved the final version of the manuscript and agree to be accountable for all aspects of the work.
Funding
The authors have nothing to report.
Conflicts of Interest
The authors declare no conflicts of interest.
Supporting information
Acknowledgements
We have used Grammarly to optimize language and Claude AI to cut down lengthy paragraphs to fit journal guidelines. AI has not been used for generating text.
References
Abril Ochoa, L.
, Naeem F., White D. J., Bijur P. E., and Friedman B. W.. 2020. “Opioid‐Induced Euphoria Among Emergency Department Patients With Acute Severe Pain: An Analysis of Data From a Randomized Trial.” Academic Emergency Medicine
27: 1100–1105. 10.1111/acem.13946.
Aghamohammadi, D.
, Gholipouri C., Hosseinzadeh H., Khajehee M. A., Ghabili K., and Golzari S. E.. 2012. “An Evaluation of the Effect of Morphine on Abdominal Pain and Peritoneal Irritation Signs in Patients With Acute Surgical Abdomen.” Journal of Cardiovascular and Thoracic Research
2012: 45–48.
Agodirin, O.
, Oguntola A., Adeoti M., Agbakwuru A., Oluwadiya K., and Olofinbiyi B.. 2013. “Preoperative Pain Treatment in Acute Abdomen in Osogbo, Nigeria: A Randomized Double‐Blind Placebo‐Controlled Study.” International Journal of Emergency Medicine
6: 3. 10.1186/1865-1380-6-3.
Antevil, J. L.
, Buckley R. G., Johnson A. S., Woolf A. M., Thoman D. S., and Riffenburgh R. H.. 2005. “Treatment of Suspected Symptomatic Cholelithiasis With Glycopyrrolate: A Prospective, Randomized Clinical Trial.” Annals of Emergency Medicine
45: 172–176. 10.1016/j.annemergmed.2004.06.017.
Bailey, B.
, Bergeron S., Gravel J., Bussières J. F., and Bensoussan A.. 2007. “Efficacy and Impact of Intravenous Morphine Before Surgical Consultation in Children With Right Lower Quadrant Pain Suggestive of Appendicitis: A Randomized Controlled Trial.” Annals of Emergency Medicine
50: 371–378. 10.1016/j.annemergmed.2007.04.018.
Bailey, B.
, Bergeron S., Gravel J., and Daoust R.. 2007. “Comparison of Four Pain Scales in Children With Acute Abdominal Pain in a Pediatric Emergency Department.” Annals of Emergency Medicine
50: 379–383.e2. 10.1016/j.annemergmed.2007.04.021.
Bartfield, J. M.
, Flint R. D., McErlean M., and Broderick J.. 2003. “Nebulized Fentanyl for Relief of Abdominal Pain.” Academic Emergency Medicine
10: 215–218. 10.1197/aemj.10.3.215.
Bigalke, S.
, Maeßen T. V., Schnabel K., et al. 2021. “Assessing Outcome in Postoperative Pain Trials: Are We Missing the Point? A Systematic Review of Pain‐Related Outcome Domains Reported in Studies Early After Total Knee Arthroplasty.” Pain
162: 1914–1934. 10.1097/j.pain.0000000000002209.
Birnbaum, A.
, Schechter C., Tufaro V., Touger R., Gallagher E. J., and Bijur P.. 2012. “Efficacy of Patient‐Controlled Analgesia for Patients With Acute Abdominal Pain in the Emergency Department: A Randomized Trial.” Academic Emergency Medicine
19: 370–377. 10.1111/j.1553-2712.2012.01322.x.
Bova, G.
, de Paepe A. L., Nicholson K. M., Wandner L. D., and Pogatzki‐Zahn E. M.. 2025. “Moving Beyond Pain Intensity as the Primary Outcome Measure: The INTEGRATE Pain Framework and Beyond.” Pain
166: S91–S94.
Bova, G.
, Domenichiello A., Letzen J. E., et al. 2023. “Developing Consensus on Core Outcome Sets of Domains for Acute, the Transition From Acute to Chronic, Recurrent/Episodic, and Chronic Pain: Results of the INTEGRATE‐Pain Delphi Process.” EClinicalMedicine
66: 102340. 10.1016/j.eclinm.2023.102340.
Cervero, F.
1991. “Mechanisms of Acute Visceral Pain.” British Medical Bulletin
47, no. 3: 549–560.
Cervero, F.
2010. “Visceral Versus Somatic Pain: Similarities and Differences.” Digestive Diseases
27: 3–10.
Chambers, C. T.
2018. “From Evidence to Influence: Dissemination and Implementation of Scientific Knowledge for Improved Pain Research and Management.” Pain
159: S56–S64.
Chang, A. K.
, Bijur P. E., Lupow J. B., and John Gallagher E.. 2013. “Randomized Clinical Trial of Efficacy and Safety of a Single 2‐Mg Intravenous Dose of Hydromorphone Versus Usual Care in the Management of Acute Pain.” Academic Emergency Medicine
20: 185–192. 10.1111/acem.12071.
Chinn, E.
, Friedman B. W., Naeem F., et al. 2019. “Randomized Trial of Intravenous Lidocaine Versus Hydromorphone for Acute Abdominal Pain in the Emergency Department.” Annals of Emergency Medicine
74: 233–240. 10.1016/j.annemergmed.2019.01.021.
Cooper, S. A.
, Desjardins P. J., Turk D. C., et al. 2016. “Analgesic Clinical Trials in Acute Pain : IMMPACT Recommendations.” Pain
157: 288–301.
Cozzi, G.
, Zanchi C., Chiaretti A., et al. 2019. “Administering Analgesia Sublingually Is a Suitable Option for Children With Acute Abdominal Pain in the Emergency Department.” Acta Paediatrica
108: 143–148. 10.1111/apa.14514.
Crisman, E.
, Appenzeller‐Herzog C., Tabakovic S., Nickel C. H., and Minotti B.. 2024. “Multidimensional Versus Unidimensional Pain Scales for the Assessment of Analgesic Requirement in the Emergency Department: A Systematic Review.” Internal and Emergency Medicine
19: 1463–1471. 10.1007/s11739-024-03608-5.
Crombez, G.
, Veirman E., Van Ryckeghem D., Scott W., and De Paepe A.. 2023. “The Effect of Psychological Factors on Pain Outcomes: Lessons Learned for the Next Generation of Research.” Pain Reports
8: E1112. 10.1097/PR9.0000000000001112.
Deaton, T.
, Auten J. D., and Darracq M. A.. 2015. “Nebulized Fentanyl vs Intravenous Morphine for ED Patients With Acute Abdominal Pain: A Randomized Double‐Blinded, Placebo‐Controlled Clinical Trial.” American Journal of Emergency Medicine
33: 791–795. 10.1016/j.ajem.2015.03.046.
Drewes, A. M.
, Olesen A. E., Farmer A. D., Szigethy E., Rebours V., and Olesen S. S.. 2020. “Gastrointestinal Pain.” Nature Reviews. Disease Primers
6: 2.
Firdous, S.
, Berger A., Jehangir W., et al. 2021. “How Should we Assess Pain: Do Patients Prefer a Quantitative or Qualitative Scale? A Study of Patient Preferences.” American Journal of Hospice & Palliative Medicine
38: 383–390. 10.1177/1049909120945599.
Gagnier, J. J.
, Lai J., Mokkink L. B., and Terwee C. B.. 2021. “COSMIN Reporting Guideline for Studies on Measurement Properties of Patient‐Reported Outcome Measures.” Quality of Life Research
30: 2197–2218. 10.1007/s11136-021-02822-4.
Gallagher, E. J.
, Esses D., Lee C., Lahn M., and Bijur P. E.. 2006. “Randomized Clinical Trial of Morphine in Acute Abdominal Pain.” Annals of Emergency Medicine
48: 150–160.e4. 10.1016/j.annemergmed.2005.11.020.
Giacosa, A.
, Riva A., Petrangolini G., et al. 2022. “Positive Effects of a Lecithin‐Based Delivery Form of
Boswellia serrata
Extract in Acute Diarrhea of Adult Subjects.” Nutrients
14: 1858. 10.3390/nu14091858.
Green, R.
, Bulloch B., Kabani A., Hancock B. J., and Tenenbein M.. 2005. “Early Analgesia for Children With Acute Abdominal Pain.” Pediatrics
116: 978–983. 10.1542/peds.2005-0273.
Hjermstad, M. J.
, Fayers P. M., Haugen D. F., et al. 2011. “Studies Comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for Assessment of Pain Intensity in Adults: A Systematic Literature Review.” Journal of Pain and Symptom Management
41: 1073–1093. 10.1016/j.jpainsymman.2010.08.016.
Joseph, N.
, Kuhlmann L., Lucocq J., et al. 2025. “A Systematic Review of Pain Assessment Domains in Acute Pancreatitis Randomised Controlled Trials.” Pancreas
27: S560–S561. 10.1016/j.hpb.2025.07.642.
Kanesan, K.
, and Rahman N. N.. 2023. “The Efficacy of Patient Controlled Analgesia for Acute Non Traumatic Abdominal Pain in Emergency Department. 22”.
Kang, J.
, Zhang W., Zeng L., et al. 2021. “The Modified Endoscopic Retrograde Appendicitis Therapy Versus Antibiotic Therapy Alone for Acute Uncomplicated Appendicitis in Children.” Surgical Endoscopy
35: 6291–6299. 10.1007/s00464-020-08129-8.
Kang, K.
, Kim W. J., Kim K., et al. 2015. “Effect of Pain Control in Suspected Acute Appendicitis on the Diagnostic Accuracy of Surgical Residents.” CJEM
17: 54–61. 10.2310/8000.2013.131285.
Kim, M. K.
, Strait R. T., Sato T. T., and Hennes H. M.. 2002. “A Randomized Clinical Trial of Analgesia in Children With Acute Abdominal Pain.” Academic Emergency Medicine
9: 281–287. 10.1197/aemj.9.4.281.
Kokki, H.
, Lintula H., Vanamo K., Heiskanen M., and Eskelinen M.. 2005. “Oxycodone vs Placebo in Children With Undifferentiated Abdominal Pain A Randomized, Double‐Blind Clinical Trial of the Effect of Analgesia on Diagnostic Accuracy.” Archives of Pediatrics & Adolescent Medicine
159: 320–325. 10.1001/archpedi.159.4.320.
Kruis, W.
, Meier E., Schumacher M., Mickisch O., Greinwald R., and Mueller R.. 2013. “Randomised Clinical Trial: Mesalazine (Salofalk Granules) for Uncomplicated Diverticular Disease of the Colon – A Placebo‐Controlled Study.” Alimentary Pharmacology & Therapeutics
37: 680–690. 10.1111/apt.12248.
Kuner, R.
, and Kuner T.. 2021. “Cellular Circuits in the Brain and Their Modulation in Acute and Chronic Pain.” Physiological Reviews
101: 213–258. 10.1152/physrev.00040.2019.
Lovett, S.
, Reed T., Riggs R., et al. 2021. “A Randomized, Noninferiority, Controlled Trial of Two Doses of Intravenous Subdissociative Ketamine for Analgesia in the Emergency Department.” Academic Emergency Medicine
28: 647–654. 10.1111/acem.14200.
Maeßen, T. V.
, Austenfeld E., Kaiser U., et al. 2021. “Systematic Review on Pain‐Related Outcome Domains After Sternotomy: A First Step Toward the Development of a Core Outcome Set.” Value in Health
24: 1203–1212. 10.1016/j.jval.2021.01.016.
Mahadevan, M.
, and Graff L.. 2000. “Prospective Randomized Study of Analgesic Use for ED Patients With Right Lower Quadrant Abdominal Pain.” American Journal of Emergency Medicine
18: 753–756. 10.1053/ajem.2000.16315.
Maity, C.
, and Gupta A. K.. 2019. “A Prospective, Interventional, Randomized, Double‐Blind, Placebo‐Controlled Clinical Study to Evaluate the Efficacy and Safety of
Bacillus coagulans
LBSC in the Treatment of Acute Diarrhea With Abdominal Discomfort.” European Journal of Clinical Pharmacology
75: 21–31. 10.1007/s00228-018-2562-x.
McGrath, P. J.
, Walco G. A., Turk D. C., et al. 2008. “Core Outcome Domains and Measures for Pediatric Acute and Chronic/Recurrent Pain Clinical Trials: PedIMMPACT Recommendations.” Journal of Pain
9: 771–783. 10.1016/j.jpain.2008.04.007.
McMahon, B.
, Prabhu A., Thode H. C., and Singer A.. 2024. “Transcutaneous Electrical Nerve Stimulation (TENS) Versus Sham TENS in Adult ED Patients With Abdominal Pain: A Clinical Trial.” American Journal of Emergency Medicine
76: 7–12. 10.1016/j.ajem.2023.10.035.
MD Anderson Cancer Center
. n.d.
The Brief Pain Inventory
.
Melzack, R.
1975. “The McGill Pain Questionnaire: Major Properties and Scoring Methods.” Pain
1: 277–299. 10.1016/0304-3959(75)90044-5.
Miller, J. P.
, Schauer S. G., Ganem V. J., and Bebarta V. S.. 2015. “Low‐Dose Ketamine vs Morphine for Acute Pain in the ED: A Randomized Controlled Trial.” American Journal of Emergency Medicine
33: 402–408.
Mokkink, L. B.
, Prinsen C. A. C., Bouter L. M., de Vet H. C. W., and Terwee C. B.. 2016. “The COnsensus‐Based Standards for the Selection of Health Measurement INstruments (COSMIN) and How to Select an Outcome Measurement Instrument.” Brazilian Journal of Physical Therapy
20: 105–113.
Motov, S.
, Mai M., Pushkar I., et al. 2017. “A Prospective Randomized, Double‐Dummy Trial Comparing IV Push Low Dose Ketamine to Short Infusion of Low Dose Ketamine for Treatment of Pain in the ED.” American Journal of Emergency Medicine
35: 1095–1100. 10.1016/j.ajem.2017.03.004.
Motov, S.
, Mann S., Drapkin J., et al. 2019. “Intravenous Subdissociative‐Dose Ketamine Versus Morphine for Acute Geriatric Pain in the Emergency Department: A Randomized Controlled Trial.” American Journal of Emergency Medicine
37: 220–227. 10.1016/j.ajem.2018.05.030.
Motov, S.
, Masoudi A., Drapkin J., et al. 2019. “Comparison of Oral Ibuprofen at Three Single‐Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial.” Annals of Emergency Medicine
74: 530–537. 10.1016/j.annemergmed.2019.05.037.
Motov, S.
, Rockoff B., Cohen V., et al. 2015. “Intravenous Subdissociative‐Dose Ketamine Versus Morphine for Analgesia in the Emergency Department: A Randomized Controlled Trial.” Annals of Emergency Medicine
66: 222–229.E1. 10.1016/j.annemergmed.2015.03.004.
Motov, S.
, Yasavolian M., Likourezos A., et al. 2017. “Comparison of Intravenous Ketorolac at Three Single‐Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial.” Annals of Emergency Medicine
70: 177–184. 10.1016/j.annemergmed.2016.10.014.
Moussa, M.
, Papatsoris A. G., and Chakra M. A.. 2021. “Intradermal Sterile Water Injection Versus Diclofenac Sodium in Acute Renal Colic Pain: A Randomized Controlled Trial.” American Journal of Emergency Medicine
44: 395–400. 10.1016/j.ajem.2020.04.079.
Mozafari, J.
, Maleki Verki M., Motamed H., Sabouhi A., and Tirandaz F.. 2020. “Comparing Intranasal Ketamine With Intravenous Fentanyl in Reducing Pain in Patients With Renal Colic: A Double‐Blind Randomized Clinical Trial.” American Journal of Emergency Medicine
38: 549–553. 10.1016/j.ajem.2019.05.049.
Narang, S.
, and Koli J.. 2018. “Efficacy and Safety of Fixed‐Dose Combination of Drotaverine Hydrochloride (80 mg) and Paracetamol (500 mg) in Amelioration of Abdominal Pain in Acute Infectious Gastroenteritis: A Randomized Controlled Trial.” Journal of Gastroenterology and Hepatology
33: 1942–1947. 10.1111/jgh.14370.
Nguyen, T.
, Mai M., Choudhary A., et al. 2024. “Comparison of Nebulized Ketamine to Intravenous Subdissociative Dose Ketamine for Treating Acute Painful Conditions in the Emergency Department: A Prospective, Randomized, Double‐Blind, Double‐Dummy Controlled Trial.” Annals of Emergency Medicine
84: 354–362. 10.1016/j.annemergmed.2024.03.024.
Oguzturk, H.
, Ozgur D., Turtay M. G., et al. 2012. “Tramadol or Paracetamol Do Not Effect the Diagnostic Accuracy of Acute Abdominal Pain With Significant Pain Relief‐a Prospective, Randomized, Placebo Controlled Double Blind Study.” European Review for Medical and Pharmacological Sciences
16: 1983–1988.
Ojetti, V.
, Saviano A., Brigida M., et al. 2022. “Randomized Control Trial on the Efficacy of Limosilactobacillus Reuteri ATCC PTA 4659 in Reducing Inflammatory Markers in Acute Uncomplicated Diverticulitis.” European Journal of Gastroenterology & Hepatology
34: 496–502. 10.1097/MEG.0000000000002342.
Page, M. J.
, McKenzie J. E., Bossuyt P. M., et al. 2021. “The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews.” BMJ
372: n71.
Petruzziello, C.
, Migneco A., Cardone S., et al. 2019. “Supplementation With
Lactobacillus reuteri
ATCC PTA 4659 in Patients Affected by Acute Uncomplicated Diverticulitis: A Randomized Double‐Blind Placebo Controlled Trial.” International Journal of Colorectal Disease
34: 1087–1094. 10.1007/s00384-019-03295-1.
Pogatzki‐Zahn, E. M.
, De Lucia S., Weinmann C., et al. 2025. “A Core Outcome Set of Measurement Instruments for Assessing Effectiveness and Efficacy of Perioperative Pain Management: Results of the International IMI‐PainCare PROMPT Delphi Consensus Process.” British Journal of Anaesthesia
134: 1460–1473.
Pogatzki‐Zahn, E. M.
, Liedgens H., Hummelshoj L., et al. 2021. “Developing Consensus on Core Outcome Domains for Assessing Effectiveness in Perioperative Pain Management: Results of the PROMPT/IMI‐PainCare Delphi Meeting.” Pain
162: 2717–2736. 10.1097/j.pain.0000000000002254.
Poonai, N.
, Kumar K., Coriolano K., et al. 2020. “Hyoscine Butylbromide Versus Acetaminophen for Nonspecific Colicky Abdominal Pain in Children: A Randomized Controlled Trial.” CMAJ
192: E1612–E1619. 10.1503/cmaj.201055.
Quinn, K.
, Kriss S., Drapkin J., et al. 2018.
Analgesic Efficacy of Intranasal Ketamine Versus Intranasal Fentanyl for Moderate to Severe Pain in Children A Prospective, Randomized, Double‐Blind Study
.
Remington‐Hobbs, J.
, Petts G., and Harris T.. 2012. “Emergency Department Management of Undifferentiated Abdominal Pain With Hyoscine Butylbromide and Paracetamol: A Randomised Control Trial.” Emergency Medicine Journal
29: 989–994. 10.1136/emermed-2011-200474.
Shaballout, N.
, Aloumar A., Manuel J., May M., and Beissner F.. 2021. “Lateralization and Bodily Patterns of Segmental Signs and Spontaneous Pain in Acute Visceral Disease: Observational Study.” Journal of Medical Internet Research
23, no. 8: e27247.
Sikandar, S.
, and Dickenson A. H.. 2012. “Visceral Pain: The Ins and Outs, The Ups and Downs.” Current Opinion in Supportive and Palliative Care
6: 17–26.
Sin, B.
, Jeffrey I., Halpern Z., et al. 2019. “Intranasal Sufentanil Versus Intravenous Morphine for Acute Pain in the Emergency Department: A Randomized Pilot Trial.” Journal of Emergency Medicine
56: 301–307. 10.1016/j.jemermed.2018.12.002.
Sterne, J.
, Savović J., Page M., et al. 2019. “RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials.” BMJ
366: l4898. 10.1136/bmj.l4898.
Teo, K.
, Johnson M. H., Truter S., Pandanaboyana S., and Windsor J. A.. 2016. “Pain Assessment in Chronic Pancreatitis: A Comparative Review of Methods.” Pancreatology
16: 931–939. 10.1016/j.pan.2016.09.006.
Thomas, S. H.
, Silen W., Cheema F., et al. 2003. “Effects of Morphine Analgesia on Diagnostic Accuracy in Emergency Department Patients With Abdominal Pain: A Prospective, Randomized Trial.” Journal of the American College of Surgeons
196, no. 1: 18–31.
Vassend, O.
, Røysamb E., and Nielsen C. S.. 2013. “Five‐Factor Personality Traits and Pain Sensitivity: A Twin Study.” Pain
154: 722–728.
Veritas Health Innovation
. n.d. “Covidence Systematic Review Software”.
Villain, C.
, Wyen H., Ganzera S., et al. 2013. “Early Analgesic Treatment Regimens for Patients With Acute Abdominal Pain: A Nationwide Survey Among General Surgeons. Langenbeck's.” Archives of Surgery
398: 557–564.
Williamson, P. R.
, Altman D. G., Bagley H., et al. 2017. “The COMET Handbook: Version 1.0.” Trials
18: 1–50. 10.1186/s13063-017-1978-4.
Wu, R. R.
, Adjei‐Poku M. N., Kelz R. R., et al. 2025. “Trends in Visits, Imaging, and Diagnosis for Emergency Department Abdominal Pain Presentations in the United States, 2007–2019.” Academic Emergency Medicine
32: 20–31.
Xiao, X.
, and Zhang Y. Q.. 2018. “A New Perspective on the Anterior Cingulate Cortex and Affective Pain.” Neuroscience and Biobehavioral Reviews
90: 200–211.
Yildirim, Ç.
, and Pamukçu Günaydin G.. 2024. “Hyoscine‐n‐Butylbromide in Treating Abdominal Pain Caused by Gastroenteritis: A Double‐Blind Randomized Placebo‐Controlled Study.” Turkish Journal of Medical Sciences
54: 887–892. 10.55730/1300-0144.5864.
Zhu, C. P.
, Jiang F., Wang R. Q., et al. 2017. “Comparison of Efficacy and Safety of Hyoscine Butylbromide Versus Anisodamine for Acute Gastric or Intestinal Spasm‐Like Pain: A Randomized, Double‐Blind and Multi‐Center Phase III Trial. Title: Hyoscine Butylbromide on Abdominal Pain.” Journal of Digestive Diseases
18: 453–460.
Associated Data
Supplementary Materials
Come citare questo studio
Kuhlmann L, Knoph CS, Olesen SS, Joseph N, Windsor J, Drewes AM, Pandanaboyana S, Pogatzki-Zahn E. (2026). Pain-Related Outcome Domains and Measures in Randomized Controlled Trials of Treatment for Acute Abdominal Pain: A Systematic Review.. European journal of pain (London, England). DOI: 10.1002/ejp.70445
Consulta la pubblicazione originale ↗